Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pro Medicus Limited ( (AU:PME) ) just unveiled an announcement.
Pro Medicus Limited has disclosed a change in the holdings of director Sam Aaron Hupert, who has increased his direct interest in the company through an on-market purchase of 2,250 ordinary shares at $221.45 per share via ALLHC Pty Ltd as trustee for the Sam Hupert Family Trust. Following the transaction, Hupert’s total holding has risen marginally to 24,189,910 ordinary shares across his personal, superannuation and family trust structures, signalling ongoing alignment of the director’s financial interests with those of shareholders but without materially altering the company’s ownership structure.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian healthcare technology company that provides radiology imaging IT solutions, including picture archiving and communication systems (PACS) and related software, primarily to hospitals, imaging centres and diagnostic providers in domestic and international markets.
YTD Price Performance: -12.93%
Average Trading Volume: 173,996
Technical Sentiment Signal: Hold
Current Market Cap: A$22.72B
For a thorough assessment of PME stock, go to TipRanks’ Stock Analysis page.